📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. (2022)

First Author: Ottaviano G

Attributed to: Phase 1 evaluation of CRISPR-CAR gene edited T cells in relapsed refractory B cell acute lymphoblastic leukaemia funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1126/scitranslmed.abq3010

PubMed Identifier: 36288281

Publication URI: http://europepmc.org/abstract/MED/36288281

Type: Journal Article/Review

Volume: 14

Parent Publication: Science translational medicine

Issue: 668

ISSN: 1946-6234